Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Genetix Granted ClonePix Patent

By Drug Discovery Trends Editor | August 18, 2010

Genetix, a leading provider of solutions for imaging and image analysis, announces that it was granted a patent, US 7,776,584. Aspects of this patent are incorporated into ClonePix FL, which is used for the screening and selection of cell lines producing biopharmaceuticals.

ClonePix FL can significantly reduce the time and cost associated with recombinant protein generation. Included in the multiple claims of the patent are those that refer to the use of automated imaging and image processing to identify animal cell colony locations, a picking head with hollow pins, a method wherein animal cell colonies are stained with a fluorescent agent to assist image processing and a claim covering single cell applications.

“The power of ClonePix FL technology lies in its ability to visualise and quantify proteins secreted from thousands of clones in situ, and to select and isolate only the highest value candidates, significantly shortening timescales and simplifying downstream culture,” commented Dr. Julian F Burke, CSO: “ClonePix FL overcomes many of the drawbacks typically associated with alternative manual methods for isolating choice mammalian cell clones, such as limited dilution, which are time consuming, resource intensive and costly, and prone to cross contamination of cells and user error.”

ClonePix FL has been validated for the specific detection of secreted antibodies and monomeric proteins, cell surface proteins, and intrinsic GFP fusion proteins. It is compatible with a range of cell types including hybridoma, myeloma, HEK293, and both suspension-adapted and adherent CHO cells. Rapidly becoming industry standard, ClonePix FL increases overall productivity, leaving more time to better characterize antibodies and begin new projects. This new patent adds to the growing portfolio of patents covering Genetix’ ClonePix FL system.

Date: August 18, 2010
Source: Genetix


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE